Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151635 | 0.99 | KMT2A (0.42) | L3MBTL1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL5155027 | 0.98 | L3MBTL1 (0.44) | L3MBTL1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL1797571 | 0.89 | LMNA (0.44) | L3MBTL1KMT2AMEN1TSHRKDM4E | |
| SCHEMBL1798663 | 0.88 | LMNA (0.45) | L3MBTL1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL1803525 | 0.87 | NPC1 (0.44) | L3MBTL1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL5152604 | 0.80 | HDAC1 (0.45) | L3MBTL1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL5151551 | 0.77 | MEN1 (0.51) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL23631941 | 0.75 | L3MBTL1 (0.69) | L3MBTL1KMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL1801807 | 0.75 | SMN1; SMN2 (0.43) | KMT2AMEN1ALDH1A1MAPK1TP53 | |
| SCHEMBL5155488 | 0.74 | POLB (0.41) | KMT2AMEN1TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | L3MBTL1 4811/4885KMT2A 4267/4885MEN1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.